[mkdf_section_title position=”” show_separator=”yes” separator_position=”center” title_tag=”” disable_break_words=”no” title=”Pubblicazioni 2010″ holder_padding=”13px”]

Treatment of thromboembolism in cancer patients.

Panova-Noeva M, Falanga A.

Expert Opin Pharmacother. 2010;11(12):2049-58

PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma.

Perry JR, Julian JA, Laperriere NJ, Geerts W, Agnelli G, Rogers LR, Malkin MG, Sawaya R, Baker R, Falanga A, Parpia S, Finch T, Levine MN.

J Thromb Haemost. 2010;8(9):1959-65.

Venous thromboembolism in cancer patients: ESMO Clinical Practice Guidelines for the management.

Mandalà M, Falanga A, Roila F; ESMO Guidelines Working Group.

Ann Oncol. 2010;21 Suppl 5:v274-6.

Nitric oxide derivatives and soluble plasma selectins in patients with myeloproliferative neoplasms.

Cella G, Marchetti M, Vianello F, Panova-Noeva M, Vignoli A, Russo L, Barbui T, Falanga A.

Thromb Haemost. 2010;104(1):151-6.

Prospective study of hemostatic alterations in children with acute lymphoblastic leukemia.

Giordano P, Molinari AC, Del Vecchio GC, Saracco P, Russo G, Altomare M, Perutelli P, Crescenzio N, Santoro N, Marchetti M, De Mattia D, Falanga A.

Am J Hematol. 2010;85(5):325-30.

Acquired and inherited risk factors for developing venous thromboembolism in cancer patients receiving adjuvant chemotherapy: a prospective trial.

Mandalà M, Barni S, Prins M, Labianca R, Tondini C, Russo L, Milesi A, Cremonesi M, Zaccanelli M, Regonesi C, Moro C, Falanga A.

Ann Oncol. 2010;21(4):871-6.